---
title: "Douglas Tsao Boosts Rapport Therapeutics Price Target to $66 on Strong RAP-219 Differentiation and Robust Phase 2 Data"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295693147.md"
description: "H.C. Wainwright analyst Douglas Tsao raised Rapport Therapeutics' price target to $66 and maintained a Buy rating, citing strong Phase 2 data for RAP-219 and its mechanistic differentiation from existing therapies. Truist Financial also issued a Buy rating with a $56 price target on August 6."
datetime: "2026-08-12T16:55:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295693147.md)
  - [en](https://longbridge.com/en/news/295693147.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295693147.md)
---

# Douglas Tsao Boosts Rapport Therapeutics Price Target to $66 on Strong RAP-219 Differentiation and Robust Phase 2 Data

H.C. Wainwright analyst Douglas Tsao has maintained their bullish stance on RAPP stock, giving a Buy rating on August 6.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Douglas Tsao has given his Buy rating due to a combination of factors that strengthen the investment case for Rapport Therapeutics. After an in-depth discussion with management, he increased his price target to $66, reflecting higher conviction in RAP-219’s commercial opportunity, supported by an enhanced sales multiple and clear mechanistic differentiation versus existing therapies.

Tsao emphasizes RAP-219’s selective action on TARP γ8, which is concentrated in brain regions relevant to focal-onset seizures and acute bipolar mania, helping avoid the motor side effects seen with broader AMPA inhibitors like perampanel. He also views the Phase 2 data as robust and internally consistent, with meaningful reductions in both clinically observed seizures and RNS-measured long episodes, alongside favorable tolerability, all of which underpin his positive outlook on the program and the company.

In another report released on August 6, Truist Financial also maintained a Buy rating on the stock with a $56.00 price target.

### Related Stocks

- [RAPP.US](https://longbridge.com/en/quote/RAPP.US.md)
- [TFC.US](https://longbridge.com/en/quote/TFC.US.md)

## Related News & Research

- [Renaissance Technologies LLC Sells 109,114 Shares of Rapport Therapeutics, Inc. $RAPP](https://longbridge.com/en/news/296325369.md)
- [Rapport Therapeutics CEO Abraham Ceesay sells 51,499 shares worth $2.41 million](https://longbridge.com/en/news/295706967.md)
- [Stoke Therapeutics’ Dravet Trial Tops Enrollment Target With Zero Dropouts](https://longbridge.com/en/news/296156348.md)
- [Amylyx drug cuts low blood sugar episodes in bariatric surgery patients in key trial](https://longbridge.com/en/news/296217967.md)
- [Troutman Pepper lawyer sues firm over alleged punishment after heart attack, claims billing fraud](https://longbridge.com/en/news/296265030.md)